Press Release

Date
Title
2023-11-08
Foresee Pharmaceuticals Announces Publication of Preclinical Data in the European Heart Journal
2023-10-30
Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease
2023-10-13
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) injectable emulsion, 42 mg for the treatment of Central Precocious Puberty
2023-09-30
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium
2023-09-29
Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications
2023-09-11
Foresee Pharmaceuticals Presents Data From its Aderamastat Program at The European Respiratory Society (ERS) International Congress 2023
2023-08-29
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI®, Extending Patent Protection to 2039
2023-07-25
Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023
2023-06-27
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing
2023-06-21
Foresee Pharmaceuticals Presented Poster on MMP-12 inhibitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases

Total 29 ( 10 records per page )　　　　Next　　Go page